Healthcare Industry News: Bristol-Myers Squibb
News Release - March 19, 2009
BG Medicine: Peter Gardiner Appointed Vice President, Medical Affairs and Senior Medical OfficerWALTHAM, Mass.--(HSMN NewsFeed)--BG Medicine Inc. (BGM) today announced that Dr. Peter Gardiner has joined the organization as Vice President, Medical Affairs and Senior Medical Officer. In his role, Dr. Gardiner will be responsible for leading and coordinating investigator-initiated research projects, clinical publications and presentations and overall medical support for our clinical collaborators and research partners.
Dr. Gardiner brings over 25 years of successful experience in the pharmaceutical and medical device industries to BG Medicine. He has served as Medical Director, Global Medical Affairs & Senior Medical Officer for Bristol-Myers Squibb (BMS) Medical Imaging and Vice President, Medical Sciences for the Medical Imaging division. Prior to BMS, Peter served as Vice President, Medical Affairs for DuPont’s Medical Imaging business. Peter has held clinical research and medical affairs positions of increasing responsibility with Gensia, Inc and GD Searle & Co in both the USA and the United Kingdom. After obtaining his medical degree from Leeds University in the UK, Peter trained in internal medicine and cardiology. He is a member of the Royal College of Physicians, United Kingdom, and of the Faculty of Pharmaceutical Medicine.
“We are very pleased to have Dr. Gardiner join our team as we begin to pursue clinical applications for the diagnostic product candidates we have currently, and continue to discover through our many collaborations,” said BG Medicine President and CEO Pieter Muntendam. “Dr. Gardiner’s extensive experience and knowledge in the field of cardiology, cardiovascular medical imaging and therapeutics will be a significant asset.”
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins, and metabolites collected from bodily fluids.
Source: BG Medicine
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.